Skip Nav Destination
Issues
1 December 2019
-
Cover Image
Cover Image
ABOUT THE COVER
Pancreatic cancer is notoriously difficult to treat. One potential opportunity for targeting pancreatic cancer is through its modified amino acid metabolism. Specifically, depriving arginine-dependent tumor cells of arginine can lead to cell death. To achieve this, a polyethylene glycol (PEG)-conjugated arginine deiminase construct (ADI-PEG20) was previously designed and tested as a monotherapy in clinical studies with limited success. In the cover image, adapted from Figure 3 of the associated manuscript, Singh and colleagues demonstrate ADI-PEG20 radiosensitized pancreatic cancer cells by inducing ER stress (red fluorescence, BIP). Therefore, ADI-PEG20 could be combined with radiation therapy in patients whose tumors are arginine-dependent. Read the full study on page 2381. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Andreas Weiss; Flavia Adler; Alexandra Buhles; Christelle Stamm; Robin A. Fairhurst; Michael Kiffe; Dario Sterker; Mario Centeleghe; Markus Wartmann; Jacqueline Kinyamu-Akunda; Heiko S. Schadt; Philippe Couttet; Armin Wolf; Youzhen Wang; Patrizia Barzaghi-Rinaudo; Masato Murakami; Audrey Kauffmann; Thomas Knoepfel; Nicole Buschmann; Catherine Leblanc; Robert Mah; Pascal Furet; Jutta Blank; Francesco Hofmann; William R. Sellers; Diana Graus Porta
Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
Jian Du; Lei Yan; Raquel Torres; Xueqian Gong; Huimin Bian; Carlos Marugán; Karsten Boehnke; Carmen Baquero; Yu-Hua Hui; Sonya C. Chapman; Yanzhu Yang; Yi Zeng; Sarah M. Bogner; Robert T. Foreman; Andrew Capen; Gregory P. Donoho; Robert D. Van Horn; Darlene S. Barnard; Jack A. Dempsey; Richard P. Beckmann; Mark S. Marshall; Li-Chun Chio; Yuewei Qian; Yue W. Webster; Amit Aggarwal; Shaoyou Chu; Shobha Bhattachar; Louis F. Stancato; Michele S. Dowless; Phillip W. Iversen; Jason R. Manro; Jennie L. Walgren; Bartley W. Halstead; Matthew Z. Dieter; Ricardo Martinez; Shripad V. Bhagwat; Emiko L. Kreklau; Maria Jose Lallena; Xiang S. Ye; Bharvin K.R. Patel; Christoph Reinhard; Gregory D. Plowman; David A. Barda; James R. Henry; Sean G. Buchanan; Robert M. Campbell
Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Melissa Works; Neha Soni; Collin Hauskins; Catherine Sierra; Alex Baturevych; Jon C. Jones; Wendy Curtis; Patrick Carlson; Timothy G. Johnstone; David Kugler; Ronald J. Hause; Yue Jiang; Lindsey Wimberly; Christopher R. Clouser; Heidi K. Jessup; Blythe Sather; Ruth A. Salmon; Michael O. Ports
Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention
Susan R. Mallery; Daren Wang; Brian Santiago; Ping Pei; Caroline Bissonnette; Jayanetti Asiri Jayawardena; Steven P. Schwendeman; Richard Spinney; James Lang
Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of Nf1-Deficient Mice
Ciersten A. Burks; Steven D. Rhodes; Waylan K. Bessler; Shi Chen; Abbi Smith; Jeffrey R. Gehlhausen; Eric T. Hawley; Li Jiang; Xiaohong Li; Jin Yuan; Qingbo Lu; Max Jacobsen; George E. Sandusky; David R. Jones; D. Wade Clapp; Jaishri O. Blakeley
Large Molecule Therapeutics
Microvesicle-Mediated Delivery of Minicircle DNA Results in Effective Gene-Directed Enzyme Prodrug Cancer Therapy
Masamitsu Kanada; Bryan D. Kim; Jonathan W. Hardy; John A. Ronald; Michael H. Bachmann; Matthew P. Bernard; Gloria I. Perez; Ahmed A. Zarea; T. Jessie Ge; Alicia Withrow; Sherif A. Ibrahim; Victoria Toomajian; Sanjiv S. Gambhir; Ramasamy Paulmurugan; Christopher H. Contag
Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy
Mike W. Helms; Kerstin Jahn-Hofmann; Felix Gnerlich; Christiane Metz-Weidmann; Monika Braun; Gabriele Dietert; Petra Scherer; Kaj Grandien; Joachim Theilhaber; Hui Cao; Timothy R. Wagenaar; Max M. Schnurr; Stefan Endres; Dmitri Wiederschain; Sabine Scheidler; Simon Rothenfußer; Bodo Brunner; Lars M. König
Cancer Biology and Translational Studies
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Huai-Xiang Hao; Hongyun Wang; Chen Liu; Steven Kovats; Roberto Velazquez; Hengyu Lu; Bhavesh Pant; Matthew Shirley; Matthew J. Meyer; Minying Pu; Joanne Lim; Michael Fleming; LeighAnn Alexander; Ali Farsidjani; Matthew J. LaMarche; Susan Moody; Serena J. Silver; Giordano Caponigro; Darrin D. Stuart; Tinya J. Abrams; Peter S. Hammerman; Juliet Williams; Jeffrey A. Engelman; Silvia Goldoni; Morvarid Mohseni
Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts
Tianshu Feng; Javad Golji; Ailing Li; Xiamei Zhang; David A. Ruddy; Daniel P. Rakiec; Felipe C. Geyer; Jane Gu; Hui Gao; Juliet A. Williams; Darrin D. Stuart; Matthew J. Meyer
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.